-Optimized movement speeds, which allow for safe and precise motion of the PPS. The range of speed and motion with the pitch-and-roll axes of the robot is restricted to reduce the sensation of movement when the patient is on the table
-Improved ergonomics. There are no moving parts in the floor system that supports the device, which allows greater accessibility to the treatment area for patients and therapists
The new PPS is part of ProCure's strategy to make proton therapy better and more accessible. This includes making the therapy more cost effective and creating a platform that will allow easy integration of future advanced image-guided proton treatments. ProCure has partnered with IBA since 2005 to implement this strategy. The FDA clearance of this new generation PPS is an essential milestone in this effort.
Ad Statistics
Times Displayed: 109945
Times Visited: 6642 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
About ProCure Treatment Centers, Inc.
ProCure Treatment Centers, Inc., based in Bloomington, Ind., was founded in 2005 to improve the lives of patients with cancer by increasing access to proton therapy. ProCure collaborates with leading radiation oncology practices and hospitals and provides management leadership and a comprehensive approach for the design, construction, financing, staffing, training and day-to-day operations of world-class proton therapy centers. ProCure's solution reduces the time, cost and effort necessary to create a facility. ProCure is the only company in the world with two proton therapy centers under construction and two others in development. ProCure's Training and Development Center is the first facility in the world dedicated to proton therapy. For more information, visit www.procure.com
About Ion Beam Applications S.A. (IBA)
IBA develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization. Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index.
www.iba-worlwide.com
Read an update on proton therapy in the May 2009 issue of DOTmed Business News Back to HCB News
